

1 **Cytoprotective and Antioxidant Properties of the Stem**
2 **Bark Aqueous extract of *khaya grandifoliola***
3 **(Meliaceae) in Rats**

4 **ABSTRACT**

5 **Aims:** To evaluate the qualitative chemical composition of the aqueous extract of the stem bark
6 of *Khaya grandifoliola* and test the antiulcer actions on gastric lesions induced by HCl/Ethanol,
HCl/Ethanol/Indomethacin, indomethacin, absolute ethanol, cold/restraint stress and pylorus
ligation in experimental Wistar rats.

Study design: Random allocation of male rats to groups of five rats each.

Place and Duration of Study: Department of Animal Biology and Physiology, Animal
Physiology Laboratory (Gastroenterology Unit), University of Yaoundé 1, between November
2014 and May 2015.

Methodology: Gastric ulcers were produced in the glandular regions of rat stomachs using
standard models of gastric ulcer induction. Ulcers produced were scored and mucus production
and the severity of ulceration were compared between control groups and those given the plant
extract or reference drugs. Oxidative stress parameters (superoxide dismutase (SOD),
malondialdehyde (MDA), reduced glutathione (GSH), catalase (CAT)) were measured in tissue
samples of rats subjected to the cold/restraint stress method.

Results: Phenols, saponinins, flavonoids, proteins, acids, anthocyanins, tannins, alkaloids,
ketones, sugars, coumarins, quinones, and amino acids were among the phytochemicals
detected. The extract (250–500 mg/kg) inhibited the formation of gastric ulcers and significantly
reduced the ulcer index in all models used (81.8 % ($p < 0.001$) with HCl/ethanol; 88.2 % ($p < 0.001$)
with absolute ethanol; 100 % ($p < 0.05$) with HCl/ethanol/indomethacin; 72.6 % with
cold/restraint stress ulcers, and 69.6 % ($P < 0.01$) with pylorus ligation at the highest dose of 500
mg/kg. Gastric acidity significantly ($p < 0.01$) dropped from 88 mEq/L in the controls to 34 mEq/L
at the dose of 500 mg/kg. In cold/restraint-induced stress, *K. grandifoliola* (500 mg/kg) lowered
the increased levels of malondialdehyde (MDA) from 2.90 (control group) to 0.46 nmol/g tissue.
The reduced levels of catalase were also significantly improved in rats treated with extract.

Conclusion: *K. grandifoliola* aqueous extract possesses gastric antiseecretory potential. Its
cytoprotective activity can be attributed to its ability to increase the antioxidant status and to
enhance gastric mucosal defense possibly through the mediation of endogenous
prostaglandins.

7
8 *Keywords: Khaya grandifoliola*, gastric ulcer, cytoprotection, antioxidant activity.
9

10 11 **1. INTRODUCTION** 12

13 Gastric ulcers are caused by the creation of an imbalance between gastric mucosal integrity and
14 aggressive factors. For the maintenance of mucosal integrity, different therapeutic agents, including plant
15 extracts, are used to inhibit gastric acid secretion or to stimulate the mucosal defense mechanism by
16 increasing the mucosal production of mucus, bicarbonate, endogenous prostaglandins and surface
17 epithelial cells [1]. Various factors can contribute to the formation of gastric ulcer including infection of the
18 stomach by *Helicobacter pylori* [2] and the frequent use of nonsteroidal anti-inflammatory drugs (NSAIDs)
19 [3]. In the West, peptic ulcer disease frequently touches 8 to 10 persons out of 100 residents [4]. The
20 introduction of endoscopy in Africa at the beginning of the 1980s helped to reveal the high degree of
21 prevalence of the disease in the pathology of the black Africans [5], and the prevalence of gastric ulcers
22 in Cameroon has been estimated at about 31.65 % [6]. The success of commercially available antiulcer
23 drugs in the treatment of gastric ulcer is usually overshadowed by various side effects. For example, H₂-
24 receptor antagonists like cimetidine may cause gynecomastia in men and galactorrhoea in women [7] while
25 proton-pump inhibitors (e.g. omeprazole and lansoprazol) can cause nausea, abdominal pain,
26 constipation and diarrhea [8, 9]. Due to these side effects, there is a need to find new antiulcer
27 compounds with potentially less or no side effects and medicinal plants have always been the main
28 source of new drug candidates for the treatment of gastric ulcer [10, 11].
29

30 *Khaya grandifoliola* (WELW) C.DC. (Meliaceae) is also called African Mahogany, Benin Mahogany,
31 Large-leaved Mahogany, Senegal Mahogany. The species occurs in all of inter-tropical Africa (Benin, The
32 Democratic Republic of the Congo, Ivory Coast, Ghana, Guinea, Nigeria, Sudan, Cameroun, Togo and
33 Uganda) at the transition zone between dense forest and savanna [12]. This important timber species,
34 commonly confused with *Khaya anthotheca*, occurs more frequently in dry semi-deciduous forest and
35 forest outliers than *K. anthotheca*. *K. grandifoliola* is classified under the Red List Category & Criteria as
36 "Vulnerable A1 cd". It has been threatened by comprehensive exploitation of mature stands from
37 subpopulations as well as by its poor regeneration capacity. For these reasons, various countries have
38 created protected subpopulations and continue to enforce log export bans [13].

39 *K. grandifoliola* is used in Cameroonian folk medicine for the treatment of pneumonia, intestinal
40 helminthiasis [12], hepatitis and other liver related-diseases [14, 15]. The stem bark extract is used in
41 Nigeria as an anticonvulsant [16]. Bark extracts of various species of the genus *Khaya* are used in West
42 African ethnomedicine to treat fever, cough, lumbago, rheumatism, stomach ache gastric pains, and

43 diarrhea in horses and camels [17]. Limonoids obtained from *K. grandifoliola* [18] were shown to be
44 responsible for the antimalarial activity of the stem bark extract [19], whose schizonticidal activity in
45 early *Plasmodium berghei berghei* infection in mice had earlier been demonstrated [20]. The bark extract
46 of *K. grandifoliola* enhanced the antiplasmodial effects of two commercialized antimalarial drugs,
47 halofantrine and chloroquine, in a mouse model of *Plasmodium yoelii nigerense* [21]. The n-hexane
48 extract, the crude and purified fractions from *K. grandifoliola* bark gave significant (91%)
49 chemosuppression of a multi-drug resistant clone of *Plasmodium berghei berghei* *in vivo* and significant *in*
50 *vitro* antiplasmodial activities against Nigerian *P. falciparum* isolates [19]. The bark extract of *K.*
51 *grandifoliola* has been shown to possess antiinflammatory [22], antioxidant [23], anti-insecticidal [24],
52 hepatoprotective [25] and antimicrobial activity against bacterial isolates of *Bacillus subtilis*, *Klebsiella*
53 *pneumoniae* and *Proteus mirabilis* [26]. The effects of the bark extract on red blood cells and bone
54 mineral content in rats [27] and on some biochemical parameters in rats [28] have also been
55 demonstrated. Analysis of the proximate, phytochemical and mineral element composition of *K.*
56 *grandifoliola* revealed that the bark extract is rich in proteins, carbohydrates, minerals such as
57 magnesium, calcium, sodium, potassium, magnesium, iron and manganese, as well as in secondary
58 metabolites including saponins, tanins, alkaloids, anthraquinones, flavonoids, reducing sugars and
59 phlobatanins [29]. Previous work has shown the antisecretory potential, and the cytoprotective activity of
60 the bark methanol extract of a sister species (*K. senegalensis*) against absolute ethanol-induced gastric
61 lesions [30]. Although *K. grandifoliola* was not cited for its antiulcer potential by the OAU/STRC-
62 sponsored ethnobotanical survey in Cameroon [12], the plant is well known in the Bamoun area (local
63 name, *Fah, Faturtu, Fatiti*) for its usefulness in the treatment of peptic ulcers. In the present study, we
64 evaluated the cytoprotective and antioxidant actions of the decoction of *K. grandifoliola* against various
65 ulcerogens. The possible modes of action of the extract are discussed in relation to the pathogenic
66 mechanisms of action of the various necrotizing agents use.

67
68
69
70
71

2. MATERIAL AND METHODS

2.1 Preparation of plant extract

72 The fresh stem-bark of *K. grandifoliola*, was collected in Mbokam village (Jakiri) in the North West Region
73 of Cameroon. Botanical identification was done at the National Herbarium in Yaoundé by comparison with
74 existing herbarium specimen No. PM 098 /95. The fresh bark was cut up, dried and ground to a powder.
75 1 kg of the dried material was boiled in 5 liters of water for 30 minutes. The extract solution was filtered
76 through four layers of cheesecloth, then through Whatman filter paper No. 3. The resulting extract
77 solution was evaporated at 40°C using a convection air oven (Jencons-PLS, UK) to obtain 66.35 g of a
78 red powder. The extract re-dissolved readily in distilled water which was used as the vehicle.

79
80

2.2 Animals

81
82 Male Wistar rats (147–180 g) raised on a standard laboratory diet and tap water in the animal house of
83 the Faculty of Science, University of Yaounde 1, were used. Prior authorization for the use of laboratory
84 animals in this study was obtained from the Cameroon National Ethics Committee (Reg. No. FWA-
85 IRB00001954). The use, handling and care of animals were done in adherence to the European
86 Convention (Strasbourg, 18.III.1986) for the protection of vertebrate animals used for experimental and
87 other purposes (ETS-123).

88 89 **2.3 Phytochemical tests**

90
91 **Phytochemical tests for the major metabolites of the extract were performed using standard protocols**
92 **[31].** The aqueous extract of *K. grandifoliola* was screened for the presence of biologically active
93 compounds such as tannins, alkaloids, saponins, flavonoids, anthocyanins, phenols, quinones,
94 coumarins, sterols, triterpenoids, glycosids and proteins. Based on the intensity of coloration, the lather or
95 the precipitate formed during the test, secondary metabolite proportions were characterized as present
96 (++) or weakly present (+) when the test result was positive, and absent (–) when the test result was
97 negative.

98 99 **2.4 Induction of gastric ulcers**

100 101 **2.4.1 HCl/ethanol-induced gastric lesions in rats**

102
103 The rats were deprived of food for 36 h prior to experimentation but all the animals had free access to tap
104 water. The HCl/ethanol solution was used to induce ulcers in the gastric mucosa according to the method
105 of [32]. The animals received the extract by oral route, 1 h before they were given the necrotizing solution.
106 Positive control rats received Sucralfate in place of the extract. They were killed another hour later using
107 ether, the abdomen of each opened and the stomachs removed. The ulcers produced in the glandular
108 region of each stomach were measured and scored, and the ulcer index (UI), percentage of inhibition (%
109 I) and percentage of ulcerated surface (%US) were calculated [33].

110 111 **2.4.2 Absolute ethanol-induced gastric lesions**

112
113
114 The method described above for the HCl/ethanol method was used, the only difference being that 1 ml of
115 absolute ethanol was used as the necrotizing solution.

116 117 **2.4.3 HCl/ethanol-induced lesions in rats pre-treated with indomethacin**

118
119 Indomethacin was given to the rats (20 mg/kg) by intra peritoneal route at the end of the 24 h fast. This
120 was followed 1 h later by the HCl/ethanol ulcer procedure as described above.

121 122 **2.4.4 Indomethacin-induced gastric lesions**

123
124 The animals were **deprived** of food for 36 hours. The vehicle and the extract (250 and 500 mg/kg) were
125 given to them 3 times at 12-hour intervals. Indomethacin (50 mg/kg) was given to the rats by oral route 1
126 hour after the animals received the last administration of the plant extract and vehicle. They were
127 sacrificed another hour later and the ulcers produced in the glandular region of the stomachs were
128 measured and expressed according to the score described by [33]. Petechial lesions were counted and
129 every five lesions were taken as 1 mm of ulcer [34].

130 131 **2.4.5 Pylorus ligated gastric secretion and ulceration in rats**

132
133 The method of Shay et al. [35] was used to study the ability of the extract to reduce gastric acid secretion
134 as well as prevent gastric ulceration resulting from auto digestion by stomach secretions. The test rats
135 received the extract, while the controls received distilled water (1ml) or Cimetidine. One hour later,
136 laparotomy was performed under ether anesthesia, the pylorus of each rat was ligatured, and the
137 abdominal incisions stitched up. The gastric juice produced during six subsequent hours was collected
138 from each rat, the volume measured and 1 ml aliquots kept for gastric acid measurement. The ulcers
139 produced in the glandular region of the stomachs were measured and ulcer index, % of inhibition, and %
140 of ulcerated surface were determined.

141 142 **2.4.6 Cold stress-induced gastric lesions**

143
144 Stress-induced gastric ulcers were provoked in rats using a slight modification of the method earlier
145 described by [36]. The animals were deprived of food for 36 hours (but not water deprivation). Test rats
146 were given the extract (250 and 500 mg/kg) by oral route while control rats received the vehicle or
147 Cimetidine three times at 12-hour intervals. One hour later, after the last administration of vehicle or
148 extract, the rats were placed in small individual wire cages and immersed in cold water ($20 \pm 1^\circ\text{C}$), up to
149 the level of the xiphoid. Three hours later blood samples were taken and the animals were sacrificed
150 using ether and the stomachs removed. The same protocol used with the indomethacin model for the
151 assessment of lesion formation was performed. Blood and gastric tissue samples were taken, prepared
152 and preserved frozen for the measurement of different oxidative stress parameters.

153 154 **2.5. Measurement of mucus production**

155
156 The mucus covering of each stomach was gently scraped using a glass slide and the mucus weighed
157 using a sensitive digital electronic balance.

158 159 **2.6 Measurement of *in vivo* antioxidant capacity**

160
161 Blood and gastric tissue samples were taken and prepared for the measurement of different oxidative
162 stress parameters: Cellular glutathione (GSH) was measured based on the reaction between 2,2-dithio-

163 5,5-dibenzoic acid and the thiol (SH) groups of glutathione to yield a complex whose absorbance was
 164 read at 412 nm [37]. The glutathione concentration was calculated using the molar extinction coefficient
 165 $\epsilon = 1.36 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$. Superoxide dismutase (SOD) activity was measured using a standard method
 166 [38], and expressed in U/mg of protein, while catalase was determined [39] and expressed as mM of
 167 $\text{H}_2\text{O}_2/\text{min}/\text{mg}$ of protein, and tissue protein was measured using the Biuret method of protein assay. Lipid
 168 peroxidation was assessed by measuring the levels of malondialdehyde [40]. Quantification of MDA was
 169 done using an extinction coefficient of $\epsilon = 1.56 \times 10^5 \text{ M}^{-1} \text{ cm}^{-1}$.

170

171 **2.7 Statistical analysis**

172 The data were analyzed using the one way analysis of variance (ANOVA) followed by the student-
 173 Newman-Keuls test. *P* values <.05 were considered significant. Values in tables are given as arithmetic
 174 means \pm standard error of the mean (S.E.M.)

175

176 **3. RESULTS**

177

178 **3.1 Phytochemical screening**

179

180 Phytochemical screening of the bark extract of *K. grandifoliola* revealed the presence of many
 181 phytoconstituents. These included phenols, saponinins, flavonoids, proteins, acids, (+++), anthocyanins
 182 (++) , tannins, alkaloids, ketones, sugars, coumarins; quinines, and amino acids (+). Oils, sterols,
 183 triterpenoids, glycosides and resins (-) were absent.

184

185 **3.2 Anti-ulcer activity**

186

187 The effects of HCl/ethanol-induced gastric lesions in rats are shown in Table 1. Control rats developed
 188 hemorrhagic lesions in the glandular portions of their stomachs 1 hour after induction of the lesions. *K.*
 189 *grandifoliola* (250–500 mg/kg) prevented the formation of gastric lesions, inhibition attaining 81.8 % at the
 190 dose of 500 mg/kg. Sucralfate (100 mg/kg) prevented lesion formation by 30.5%. Mucus production
 191 increased from 85.4 mg in the controls to 105.9 mg for Sucralfate and 129.4 mg for the highest dose of
 192 extract.

193

194

195 **Table 1. Effect of *K. grandifoliola* extract on HCl/ethanol-induced gastric lesions in rats.**

<i>Treatment</i>	<i>Dose (mg.kg)</i>	<i>N</i>	<i>Ulcer index</i>	<i>% ulcerated surface</i>	<i>Inhibition %</i>	<i>Mucus production (mg)</i>
Control	-	5	4.03 \pm 0,13	5.29	-	85.41 \pm 5.55
<i>K. grandifoliola</i>	250	5	2.25 \pm 0.33*	2.87	44.16	119.8 \pm 20.90*
<i>K. grandifoliola</i>	500	5	0.73 \pm 0.045**	0.43	81.77	129.4 \pm 9.23*
Sucralfate	100	5	2.80 \pm 0.97*	1.13	30.45	105.9 \pm 12.17*

196 Statistically different relative to control; ** $P < 0.01$; N , number of rats. The values are expressed as mean \pm
 197 SEM.
 198

199
 200 Table 2 shows that pre-treatment with indomethacin followed by HCl/ethanol significantly increased the
 201 ulcerated surface area (7.3%) compared with the HCl/ethanol treatment alone (5.3%). Ulcer index
 202 reduced significantly from 4.04 ± 0.13 for the vehicle control to 2.99 ± 0.09 for the maximal dose of extract.
 203 Although per cent inhibition of ulcer in all the extract-treated groups dropped considerably compared with
 204 those obtained with the HCl/ethanol model, the cytoprotection was accompanied by significant increase in
 205 mucus production, from 70.03 mg in the vehicle control to 103 mg for the highest dose of extract.

206
 207 **Table 2. Effect of *K. grandifoliola* extract on HCl/ethanol-induced gastric lesions in rats pre-**
 208 **treated with indomethacin.**

<i>Treatment</i>	<i>Dose</i> (mg.kg)	<i>N</i>	<i>Ulcer index</i>	<i>% ulcerated</i> <i>surface</i>	<i>Inhibition</i> %	<i>Mucus production</i> (mg)
Control	-	5	4.04 ± 0.13	7.32	-	70.03 ± 9.87
<i>K. grandifoliola</i>	250	5	$3.13 \pm 0.09^*$	6.42	23.32	79.96 ± 18.37
<i>K. grandifoliola</i>	500	5	$2.99 \pm 0.09^{**}$	5.36	25.94	$103.30 \pm 11.11^{**}$
Sucralfate	100	5	$2.55 \pm 0.33^{***}$	4.18	36.98	59.40 ± 6.81

209
 210 Statistically different relative to control; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; N , number of rats. The values are
 211 expressed as mean \pm SEM.
 212
 213

214 Table 3 shows that the extract significantly prevented gastric lesions induced by absolute ethanol, with
 215 88.2% protection at the maximal dose, (ulcer index 0.48 ± 0.30 , compared with 4.08 ± 0.29 for the
 216 negative control).

217
 218
 219 **Table 3. Effect of *K. grandifoliola* extract on absolute ethanol-induced gastric lesions in rats.**
 220

<i>Treatment</i>	<i>Dose</i> (mg.kg)	<i>N</i>	<i>Ulcer index</i>	<i>% ulcerated</i> <i>surface</i>	<i>Inhibition</i> %	<i>Mucus production</i> (mg)
Control	-	5	4.08 ± 0.29	6.53	-	95.96 ± 4.34
<i>K. grandifoliola</i>	250	5	$1.20 \pm 0.51^{***}$	0.43	70.57	82.00 ± 3.74
<i>K. grandifoliola</i>	500	5	$0.48 \pm 0.30^{***}$	0.07	88.23	86.00 ± 9.27
Sucralfate	100	5	$2.43 \pm 0.47^*$	1.44	40.31	77.44 ± 10.32

221 Statistically different relative to control; * $P < 0.05$; *** $P < .001$; N , number of rats. The values are expressed
 222 as mean \pm SEM
 223
 224

225 Treatment with indomethacin produced lesions in the stomach glandular region (ulcer index, 2.87 ± 0.60)
 226 of control rats (Table 4). Extract administration significantly protected the glandular stomach against
 227 indomethacin-induced lesions (inhibition, 79 and 100% for the 250 and 500 mg/kg doses, respectively).
 228 Mucus production increased significantly with Cimetidine and was poor with extract doses compared to
 229 the values obtained with HCl/ethanol and HCl/ethanol-Indomethacin pre-treatment.

230
 231
 232
 233

Table 4. Effect of *K. grandifoliola* extracts on Indomethacin-induced gastric lesions in rats.

<i>Treatment</i>	<i>Dose (mg.kg)</i>	<i>N</i>	<i>Ulcer index</i>	<i>% ulcerated surface</i>	<i>Inhibition %</i>	<i>Mucus production (mg)</i>
Control	-	5	2.87 ± 0.60	0.86	-	26.01 ± 5.10
<i>K. grandifoliola</i>	250	5	$0.47 \pm 0.29^{***}$	0.13	79.07	16.0 ± 1.40
<i>K. grandifoliola</i>	500	5	$0.00 \pm 0.00^{***}$	0.00	100	42.0 ± 3.74
Sucralfate	100	5	$0.20 \pm 0.20^{***}$	0.003	93.02	$54.0 \pm 7.90^{**}$

234 *Statistically different relative to control; ***p<0.001; N, number of rats. The values are expressed as mean*
 235 *± SEM.*

236
 237
 238 Tables 5 and 6 show the results obtained using the pylorus ligation ulcer induction method. *K.*
 239 *grandifoliola* aqueous extract protected the stomachs against lesions with a protection percentage of
 240 **61.01 and 69.62** at the 250 and 500 mg/kg dose, respectively. The cytoprotection was accompanied by a
 241 significant decrease of ulcer indices at all the doses of *K. grandifoliola* extract, and increase in mucus
 242 protection from 30.76 ± 0.01 mg (control) to 57.86 ± 0.23 and 60.25 ± 0.22 mg, respectively, for the 250
 243 and 500 mg/kg doses (Table 5). **In comparison with the negative control (5.38 ± 0.33 ml), the volume of**
 244 **gastric juice dose-dependently reduced from 4.42 ± 0.39 to 3.61 ± 0.22 ml as the dose of extract**
 245 **increased from 100 to 500 mg/kg. This was associated with a significant reduction ($p<0.01$) in gastric**
 246 **acidity from 88 mEq/L in the controls to 34 mEq/L for Cimetidine and the 500 mg/kg dose of extract**
 247 **(Table 6).**

248
 249 **Table 5. Effect of *Khaya grandifoliola* extract on pylorus-ligated gastric ulceration in rats.**
 250

<i>Treatment</i>	<i>Dose (mg/kg)</i>	<i>N</i>	<i>Ulcer index</i>	<i>% ulcerated surface</i>	<i>Inhibition %</i>	<i>Mucus production (mg)</i>
Control	-	5	3.95 ± 0.28	1.29	-	30.76 ± 0.01
<i>K grandifoliola</i>	100	5	$1.68 \pm 0.00^{**}$	0.59	57.47	$43.92 \pm 0.49^{**}$
<i>K grandifoliola</i>	250	5	$1.54 \pm 0.04^{**}$	0.59	61.01	$57.86 \pm 0.23^{**}$
<i>K grandifoliola</i>	500	5	$1.20 \pm 0.4^{**}$	0.19	69.62	$60.25 \pm 0.22^{**}$
Cimetidine	50	5	$1.50 \pm 0.61^{**}$	0.31	62.02	$88.80 \pm 0.13^{**}$

251
 252 Statistically different relative to control; ** $p < 0.01$; N, number of rats. The values are expressed as mean \pm
 253 SEM.

254
 255
 256
 257 **Table 6. Effect of *Khaya grandifoliola* extract on gastric secretion in pylorus-ligated rats.**
 258

<i>Treatment</i>	<i>Dose (mg/kg)</i>	<i>N</i>	<i>gastric pH</i>	<i>Gastric contents (ml)</i>	<i>Gastric acidity (mEq/L)</i>
Control	-	5	2.59 \pm 0.14	5.38 \pm 0.33	88.80 \pm 0.13
<i>K grandifoliola</i>	100	5	2.85 \pm 0.01	4.42 \pm 0.39	78.5 \pm 0.50
<i>K grandifoliola</i>	250	5	2.92 \pm 0.01	4.36 \pm 0.46	71.00 \pm 2.45
<i>K grandifoliola</i>	500	5	4.44 \pm 0.02**	3.61 \pm 0.22**	34.00 \pm 1.78
Cimetidine	50	5	4.30 \pm 0.34**	4.20 \pm 0.21	35.75 \pm 0.58

259 Statistically different relative to control; ** $p < 0.01$; N, number of rats. The values are expressed as mean \pm
 260 SEM.

261
 262
 263
 264 The effects of subjecting the rats to a combination of restraint and cold stress are shown in Table 7.
 265 Control rats developed many lesions in the glandular portions of their stomachs 6 hours after cold water
 266 immersion. *K. grandifoliola* extract (250–500 mg/kg) prevented the formation of gastric lesions, inhibition
 267 attaining 72.6% at the dose of 500 mg/kg. Cimetidine (50 mg.kg) prevented lesions formation by 53.8%.

268
 269
 270 **Table 7. Effect of *K. grandifoliola* extract on cold/restraint stress-induced gastric lesions in rats.**

<i>Treatment</i>	<i>Dose (mg.kg)</i>	<i>N</i>	<i>Ulcer index</i>	<i>% ulcerated surface</i>	<i>Inhibition %</i>	<i>Mucus production (mg)</i>
Control	-	5	1.44 \pm 0.21	0.63	-	55.91 \pm 1.69
<i>K. grandifoliola</i>	250	5	1.00 \pm 0.27	0.10	31.60	57.86 \pm 8.03
<i>K. grandifoliola</i>	500	5	0.40 \pm 0.24*	0.01	72.64	63.60 \pm 3.72
Cimétidine	50	5	0.68 \pm 0.28	0.31	53.76	71.02 \pm 8.10

271 Statistically different relative to control; * $P < 0.05$; N, number of rats. The values are expressed as mean \pm
 272 SEM.

273
 274 Table 8 shows that subjection of the rats to cold restraint stress significantly decreased antioxidant
 275 enzyme activity of SOD and concentration of GSH compared with controls. Treatment with extract and
 276 cimetidine did not prevent the drop in the activity and concentration of these metabolites. The cold stress
 277 method reduced catalase enzyme activity from 5.13 \pm 0.90 $\mu\text{mol H}_2\text{O}_2/\text{min/mg}$ of protein in normal rats to
 278 4.39 \pm 0.59 $\mu\text{mol H}_2\text{O}_2/\text{min/mg}$ of protein. The highest dose of extract raised catalase activity to above
 279 normal values. The high MDA concentrations (2.90 \pm 0.44 mmol/g protein $\cdot 10^{-6}$) created by the stress
 280 method were significantly lowered in all extract-treated groups.

281
282
283
284

Table 8. Effect of *K. grandifoliola* extract on oxidative stress parameters in stomach tissues of rats subjected to cold/restraint stress-induced gastric lesions.

<i>Treatment</i>	<i>Dose (mg/kg)</i>	<i>N</i>	<i>SOD (U/mg protéine)</i>	<i>Catalase ($\mu\text{mol H}_2\text{O}_2/\text{min/mg of protein}$)</i>	<i>GSH (mol/g protein . 10⁴)</i>	<i>MDA (mmol/g protein .10⁻⁶)</i>
Normal rats	-	5	8.26 ± 1.020	5.13 ± 0.90	6.99 ± 0.12	2.26 ± 0.19
Control	-	5	4.55 ± 0.003	4.39 ± 0.59	2.52 ± 0.56	3.30 ± 0.02
<i>K. grandifoliola</i>	250	5	4.56 ± 0.002	6.63 ± 0.17	2.61 ± 0.18	0.65 ± 0.18***
<i>K. grandifoliola</i>	500	5	4.56 ± 0.002	11.94 ± 1.66**	2.74 ± 0.31	0.46 ± 0.01***
Cimétidine	50	5	4.55 ± 0.003	7.12 ± 2.20	2.27 ± 0.30	1.05 ± 0.33**

Statistically different relative to control; ** $p < 0.01$; *** $p < 0.001$; N, number of rats. The values are expressed as mean ± SEM.

285
286
287

4. DISCUSSION

288
289
290

The present experiments were designed to validate the folk use of *K. grandifoliola* in the management of gastric ulcer, and to suggest possible modes of its cytoprotective action. Peptic ulcer and gastritis have been associated with multipathogenic factors that disturb the natural equilibrium between endogenous mucosal defense mechanisms and the mucosal aggressive factors (acid and pepsin). Experimental ulcerogenic models involving alcohol, HCl hypersecretion, NSAIDs and stress are therefore designed to tip the equilibrium in favour of gastric ulcer generation [41, 42], and the ability of candidate antiulcer agents to attenuate and possibly block the gastric acid secretion or to enhance the mucosal defense mechanisms is evaluated. The results presented here show that the aqueous extract of *K. grandifoliola* protected the gastric mucosa against damage induced by pylorus ligation, HCl/ethanol, absolute ethanol, indomethacin and cold/restraint stress, models commonly used to evaluate gastric ulceration in rodents.

301

HCl/ethanol- and absolute ethanol-induced ulcers were significantly inhibited (81.8 % and 88.2 %, respectively) at the highest dose of extract whereas Sucralfate showed 30.5 and 40.3 % inhibition against the two models. The HCl/ethanol solution directly irritates the stomach mucosa, reduces mucosal resistance and erodes the mucosal barrier. The highly corrosive nature of absolute ethanol to the gastric mucosa is well known. Absolute ethanol causes gastric mucosal lesions through the release of tissue-derived mediators such as histamine and leucotriene C₄ as well as by superficial aggressive cellular necrosis. The action of these mediators on gastric microvasculature result in both mucosal and submucosal gastric tissue destruction [43]. *K. grandifoliola* extract offered significant cytoprotection against absolute ethanol (70 – 88% inhibition). This effect was not accompanied by a significant increase in mucus production, suggesting important inhibitory effects on the generation of the destructive tissue-

310
311

312 derived mediators, or inhibition of their action on the gastric microvasculature [44, 45]. Pre-treatment with
313 indomethacin led to a significant drop in cytoprotection (23.2 and 25.9% inhibition for the negative 250
314 and 500 mg/kg doses of extract, respectively). When cytoprotection against HCl/ethanol is significantly
315 reduced by pre-treatment with indomethacin, the cytoprotective action is usually interpreted to be
316 mediated through endogenous prostaglandins. Although indomethacin administered alone by oral route
317 significantly decreased mucus production in the controls (26.01 ± 5.10 mg), *K. grandifoliola* extract raised
318 mucus levels to 42.0 ± 3.74 at the dose of 500 mg/kg, and offered the highest degree of cytoprotection
319 (79 – 100% inhibition) compared with the other models. Indomethacin and other NSAIDs are well known
320 for their ability to reduce prostaglandin secretion as well as gastric mucosal blood flow, factors that are
321 highly critical to the early events in the pathogenesis of gastric ulceration. The reduced microcirculation
322 can negatively impact on the secretion of bicarbonate and mucus by the gastric and duodenal epithelium
323 and on the proliferation of epithelial cells [46, 47]. The results further lend support to the suggestion that
324 endogenous prostaglandin and gastric mucus production are involved in the cytoprotective action of the
325 extract.

326
327 Gastric acid plays a major role in the pathogenesis of gastric and duodenal ulcers [48]. Gastric acid
328 secretion is mediated by the enzyme H^+/K^+ -ATPase or by the proton pump localized on the luminal
329 membrane of parietal cells [49]. In the pyloric ligation-induced ulcer model, ulceration is caused by the
330 accumulation of acidic gastric juice in the stomach [47]. The accumulated acid, in addition to its corrosive
331 action on gastric glandular epithelium, provides the optimum pH (1.6– 3.2) for the conversion of
332 pepsinogen to pepsin. Both HCl and pepsin are important ingredients for the formation of pylorus ligated
333 ulcers [50,51]. *K. grandifoliola* extract (100, 250 and 500 mg/kg) significantly reduced the pylorus ligated
334 ulcer index, gastric acidity and the volume of gastric contents in a dose-dependent manner compared
335 with the negative controls. Gastric acid concentrations at 500 mg/kg of extract (34.0 mEq/L) were
336 comparable to those obtained with 50 mg/kg of cimetidine (35.6 mEq/L), and with 400 mg/kg of *Khaya*
337 *senegalensis* bark aqueous extract (40 mEq/L) by [30].

338
339 It was reported that doses of *K. grandifoliola* aqueous extract as low as 12.4 mg/kg completely inhibited
340 the formation of cold stress-induced lesions in rats [52]. Our results (31 and 72% inhibition for 200 and
341 400 mg/kg extract, and 54% inhibition for 50 mg/kg of cimetidine) do not confirm these unprecedented
342 reports even though our bark samples were harvested from the same ecological zone. We did not
343 observe noticeable cytoprotective effects at extract doses below 200 mg/kg.

344
345 Water immersion/restraint stress-induced gastric injury is a useful tool in the examination of the
346 pathomechanism of acute gastritis. In acute stress ulcer, intraluminal acid must be present for mucosal
347 damage to occur [53] and gastric adherent mucus plays an important role in protecting the mucosa against
348 ulceration. The stress ulcer model increases gastric acid secretion [43] and reduces gastric adherent mucus.

349 In addition, the model also stimulates the production of oxygen-derived free radicals by endothelial cells and
350 polymorphonuclear neutrophils. The free radicals, among other mechanisms, provoke tissue damage by
351 inducing ischemia and vascular endothelial cell damage through membrane lipid peroxidation, but
352 endogenous antioxidants (superoxide dismutase, glutathione and catalase) are effective in reducing the
353 adverse effects of free radicals on the gastric mucosa. The neutrophils, also produce pro-inflammatory
354 mediators that inhibit gastric ulcer healing [54-56]. In experimental rats submitted to cold/immersion stress,
355 blood concentrations of SOD, catalase and GSH decreased compared with normal rats. *K. grandifoliola*
356 extract (500 mg/kg) and cimetidine reverted the blood concentrations of catalase (but not SOD and GSH)
357 back to levels greater than normal. SOD converts superoxide free radicals into H₂O₂ which is subsequently
358 degraded by catalase. In control rats, the stress model also increased blood levels of MDA, the major
359 product of cell membrane lipid peroxidation, but both doses of *K. grandifoliola* extract significantly blocked the
360 production of MDA. These findings are evidence of the extract-induced enhancement of the antioxidant
361 status of the animals. Antioxydant activity of *K. grandifoliola* has been reported by [25]. In addition, phenols
362 and flavonoids which were found in significant quantities in the extract, are natural plant substances with well-
363 known preventive antioxidant and antiulcer activities [11, 42, 57, 58]. These compounds most likely inhibit
364 gastric mucosal injury by scavenging the indomethacin- or stress-generated oxygen metabolites [41]. The
365 gastroprotective effect may be due to the action of these compounds.

366 5. CONCLUSION

367
368 In conclusion, *K. grandifoliola* aqueous extract possesses gastric antisecretory potential. Its cytoprotective
369 activity can be attributed to its ability to increase the antioxidant status and to enhance gastric mucosal
370 defense possibly through the mediation of endogenous prostaglandins. The possible mechanism for anti-
371 secretion need to be investigated.

372

373

374 REFERENCES

375

- 376 1. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: Why doesn't the stomach
377 digest itself? *Physiol Rev.* 2008;88:1547-1565.
- 378
379 2. Phillipson M, Atuma C, Henriksnas J, Holm A. The importance of mucus layers and bicarbonate
380 transport in preservation of gastric juxtamucosal pH. *Am. J. Physiol. Gastrointest Liver Physiol.*
381 2002; 282:211-219.
- 382
383 3. Bighetti AE, Antonio MA, Kohn LK, Rehder VLG, Foglio MA, Possenti A, Vilela L, Carvalho JE.
384 Antiulcerogenic activity of a crude hydroalcoholic extract and coumarin isolated from *Mikania*
385 *laevigata* Schultz Bip. *Phytomed.* 2005;12:72-77.
- 386
387 4. Ndabaneze L, Bazira P, Kadende P, Audray R. Epidémiologie de la maladie ulcéreuse
388 gastroduodénale au Burundi. Expérience des 10 dernières années des services de médecine interne
389 et de chirurgie des hôpitaux universitaires de Bujumbura. *Médecine d'Afrique Noire.*
390 1990;37(10):529-537.

391

- 392 5. Aubrey P, Klotz, F. Contribution de l'endoscopie au diagnostic évolutif de l'ulcère duodéal. Dakar
393 Médical. 1982;27:67-71.
- 394 6. Ndjitoyap NZC, Tzeuton C, Mbacop A, Guemme TA, Njoya O, Tagne SM, Ngu LJ. Endoscopie
395 digestive au Cameroun: étude analytique de 4100 examens. Médecine d'Afrique Noire.
396 1999;37(9): 453-456.
397
- 398 7. Feldman M, Burton ME. Histamine2-Receptor Antagonists - Standard Therapy for Acid-Peptic
399 Diseases. N Engl J. 1990;323:1672-1680.
400
- 401 8. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm. 1999;56(23):S11-
402 S17.
403
- 404 9. Franko TG, Richter JE. Proton-pump inhibitors for gastric acidrelated disease. Cleve Clin J Med.
405 1998;(65):27-34.
406
- 407 10. Rates SM. (2001). Plants as source of drugs. Toxicon. 39: 603-613.
408
- 409 11. Borrelli F et Izzo AA. The Plant Kingdom as a Source of Anti-ulcer Remedies. Phytother Res. 2000;
410 14:581-591.
411
- 412 12. Adjanohoun JF, Aboubakar N, Dramane K, Ebot ME, Ekpere JA, Enow-Orock EG et al..
413 Traditional Medecine and Pharmacopoeia: Contribution to Ethnobotanical and Floristic Studies in
414 Cameroon. Organization of African Unity Scientific, Technical and Research Commission. Centre
415 National de Production des Manuels Scolaires, Porto-Novo. Benin: 1996. Pp. 22-23.
416
- 417 13. Hawthorne, W. *Khaya grandifoliola*. The IUCN Red List of Threatened Species. 1998.Version
418 2014.3. www.iucnredlist.org. Downloaded on 29 May 2015.
419
- 420 14. Mongbet, L. M. La médecine Bamoun. CEPER, Yaoundé, 1975.
421
- 422 15. Moundipa FP, Njayou FN, Yanditoum S, Sonke B, Mbiapo TF. Medicinal plants used in the
423 Bamoun region (West Cameroon) against jaundice and other liver disorders. Cam J Biol Biochem
424 Sc. 2001;2:39-46.
425
- 426 16. Awe SO, Olajide OA, Adeboye JO, Makinde JM. Pharmacological evaluation of *Khaya*
427 *grandifoliola* methanolic extract. J Pharm Res Dev. 1997;2:20-23.
428
- 429 17. Dalziel JM. The useful plants of West Tropical Africa. Crown Agents for the Colonies. London,
430 612pp. 1994.
431
- 432 18. Bickii J, Njifutie N, Ayafor JF, Basco LK, Ringwald P. *In vitro* antimalarial activity of limonoids from
433 *khaya grandifoliola* C.D.C. (Meliaceae). J Ethnopharmacol. 2000;69:27-33.
434
- 435 19. Agbedahunsi JM, Elujoba AA, Makinde JM, Oduola AMJ. Antimalarial activity of *Khaya grandifoliola*
436 stem bark. Pharm Biol. 1998;36:8-12.
- 437 20. Makinde JM, Awe SO, Agbedahunsi JM. Effect of *Khaya grandifoliola* extract in *P. berghei* in
438 mice. Phytother Res. 1988;2:30-32.
439
- 440 21. Ijarotimi SO, Agbedahunsi JM, Onyeji CO, Adewunmi CO. Chemotherapeutic interaction
441 between *Khaya grandifoliola* (Welw) CDC stem bark extract and two anti-malarial drugs in mice.
442 Afr J Tradit Complement Altern Med. 2010;7(4):370-376.
443

- 444 22. Falodun A, Poh CF, Adelusi SA, Odion E. Phytochemical and Anti inflammatory Evaluation of
445 *Khaya grandifoliola* Stem Bark Extract. Int J Pharm Tech Res. 2009;(1)4:1061-1064.
446
- 447 23. Njayou FN, Moundipa PF, Tchana AN, Ngadjui BT, Tchouanguép FM. Inhibition of microsomal
448 lipid peroxidation and protein oxidation by extracts from plants used in Bamun folk medicine
449 (Cameroon) against hepatitis. Afr J Trad CAM. 2008;5(3):278-289.
450
- 451 24. Falodun A, Siraj R, Qadir MI, Tanoli SAK, Choudhary MI. Chemical composition and insecticidal
452 activity of volatile oil of *Khaya grandifoliola*. Medicinal and Aromatic Plant Science &
453 Biotechnology. 2009;3(1):61-63.
454
- 455 25. Njayou FN, Aboudi ECE, Tandjang MK, Tchana AK, Ngadju ,BT, Moundipa PF. Hepatoprotective
456 and antioxidant activities of stembark extract of *Khaya grandifoliola* (Welw) CDC and Entada
457 africana Guill. et Perr. J Nat Prod. 2013;6:73-80.
458
- 459 26. Stephen UA, Abiodun F, Osahon O, Ewaen E. Phytochemical analysis and antibacterial activity of
460 *Khaya grandifoliola* stem bark. J Biol Sc. 2009;9(1):63-67.
461
- 462 27. Bumah VV, Essien UE, Agbedahunsi JM, Eka OU. Effects of *Khaya gradifoliola* on red blood cells
463 and bones. Phytother Res. 2005a;19:928-931.
464
- 465 28. Bumah VV, Essien UE, Agbedahunsi JM, Eka OU. Effects of *Khaya gradifoliola* on some biochemical
466 parameters in rats. J Ethnopharmacol. 2005b;102:446-449.
- 467 29. Ojokuku SA, Okunowo WO and Apena A. Evaluation of the chemical composition of *Khaya*
468 *grandifoliola* and *Ficus capensis*. J Med Plants Res. 2010;4(12):1126-1129.
469
- 470 30. Suleiman MM, Tauheed M, Babandi JS, Umar R, Sulaiman MH, Shittu M, Isa HI. In vivo
471 experimental trial to determine the efficacy of stem-bark extract of *Khaya senegalensis* A. Jus
472 (Meliaceae) for treating gastric ulcer in rat. Intl J Med Arom plants. 2013;3(3):352-361.
473
- 474 31. Bruneton, J. Photochemistry and Pharmacognosy of Medicinal plants: Technics. 2nd edition.
475 Lavoisier. 1993. Pp. 309-320.
476
- 477 32. Hara N, Okabe S. Effect of gefarnate on acute lesions in rats. Fol Pharmacol Japon. 1985;85:443-
478 448.
479
- 480 33. Tan PV, Nditafon GN, Yewah MP, Ayafor JF, Dimo T. *Eremomastax speciosa*: Effect on the leaf
481 aqueous extract on ulcer formation and gastric secretion in rats. J Ethnopharmacol. 1996;54:139-
482 142.
- 483 34. Cho CH, Ogle CW. Cholinergic-mediated gastric mast cell degranulation with subsequent
484 histamine H1- and H2-receptors activation in stress ulceration in rats. Eur J Pharmacol.
485 1979;55:23-33.
486
- 487 35. Shay JP, Komarov SA, Fels SS, Meranze D, Grunstein M, Simpler H. A simple method for the
488 uniform production of gastric ulceration in the rat. Gastroenterology. 1945;5:43-61.
489
- 490 36. Landeira-Fernandez J. Analysis of the cold-water restraint procedure in gastric ulceration and
491 body temperature. Physiology & Behavior. 2004;82:827-833.
492
- 493 37. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70-77.
494
- 495 38. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple
496 assay for superoxide dismutase. J Biol Chem. 1972;247(10):3170-3175.
497

- 498 39. Sinha AK. Colorimetric assay of catalase. *Ann Biochem.* 1972;47:389-394.
- 499 40. Wilbur KM, Bernheim F, Shapiro OW. Determination of lipid peroxidation. *Arch Biochem Biophys.*
500 1949;24:305-310.
- 501
- 502 41. Shetty BV, Arjuman A, Jorapur A, Samanth R, Yadav SK, Valliammai N, Tharian AD, Sudha K,
503 Rao GM. Effect of extract of *Benincasa hispida* on oxidative stress in rats with indomethacin-
504 induced gastric ulcers. *Ind J Physiol Pharmacol.* 2008;52(2):178-182.
- 505
- 506 42. Abdulla MA, AL-Bayaty FH, Younis LT, Abu Hassan MI. Antiulcer activity of *Centella asiatica* leaf
507 extract against ethanol-induced gastric mucosal injury in rats. *J Med Plant Res.* 2010;4(13):1253-
508 1259.
- 509
- 510 43. Oates PJ, Hakkinen JP. Studies on the mechanism of ethanol-induced gastric damage in rats.
511 *Gastroenterology.* 1985;94:10-21.
- 512
- 513 44. Muralidharan P, Srikanth J. Antiulcer activity of *Morinda citrifolia* Linn fruit extract. *J. Sci. Res.*
514 2009;1(2):345-352.
- 515
- 516 45. Tulassay Z, Herszényi L. Gastric mucosa defense and cytoprotection. *Best Pract Res clin*
517 *Gastroenterology.* 2010;24(2):49 *J Physiol.* 1982;245:601-603.
- 518 46. Miller, TA. Protective effect of prostaglandins against gastric mucosal damage: current knowledge
519 and proposed mechanisms. *American Journal of Physiology,* 1982; 245: 601-603.
- 520
- 521
- 522 76. Shawon L, Gautam P. An overview of the current methodologies used for evaluation of gastric and
523 duodenal antiulcer agents. *Pharmacologia.* 2012;3(8):249-257.
- 524
- 525 48. Hunt RH, Cederberg J, Dent F, Halter C, Hawden et al. Optimising acid suppression for treatment of
526 acid-related diseases. *Digestive Diseases and Science.* 1995;40:24S-49S.
- 527
- 528 49. Sachs G. Gastric H⁺, K⁺-ATPase as therapeutic target. *Ann Rev Pharmacol Toxicol.* 1988;28:269-
529 284.
- 530 50. Martin MJ, Marhuenda E, Perez-Guerrero C, Franco JM. Antiulcer effect of naringin on gastric
531 lesions induced by ethanol in rats. *Pharmacology.* 1994;49(3):144-150.
- 532
- 533 51. Tan PV, Nyasse B, Enow-Orock GE, Wafo P, Forcha EA. Prophylactic and healing properties of a
534 new anti-ulcer compound from *Enantia chlorantha* in rats. *Phytomedicine.* 2000;7:1-6.
- 535
- 536 52. Njifutie N, Njikam N. Curative dose of *Khaya grandifoliola* stem bark for the treatment of gastric ulcer
537 using rats. *Pharm Biol.* 2006;44:152-155.
- 538
- 539 53. Mersereau A, Hinchey EJ. Effect of gastric acidity on gastric ulceration induced by hemorrhage in the
540 rat, utilizing a gastric chamber technique. *Gastroenterology.* 1973;64(6):1130-1135.
- 541
- 542 54. Ohara SA, Toyota T. Biological evaluation of extracellular superoxide dismutase observed in a state
543 of acute gastric mucosal lesions. *Jap J Gastroenterol.* 1990;87(1):1-7.
- 544
- 545 55. Lambert G, Kinsley CH. Sex differences and gonadal hormones influence susceptibility to the
546 activity-stress paradigm. *Physiology and Behavior.* 1993;53(6):1085-1090.
- 547
- 548 56. Cheng CL, Koo MWL. Effect of *Centella asiatica* on ethanol induced gastric mucosal lesions in rats.
549 *Life Sciences.* 2000;67:2647-2653.
- 550

- 551 57. Favier A. Le stress oxydant : Intérêt conceptuel et expérimental dans la compréhension des
552 mécanismes des maladies et potentiels thérapeutique. In: Mécansismes biochimiques. L'Actu Chim.
553 2003;Nov-Dec.:108-115.
554
- 555 58. Shokunbi OS, Odetola AA. Gastroprotective and antioxidant activities of *Phyllanthus amarus* extracts
556 on absolute ethanol-induced ulcer in albino rats. J Med Plant Res. 2008;2(10):261-267.